EGFR and non-small cell lung carcinoma: AXL has been primarily studied in the context of acquired resistance, with only a few reports of elevated AXL expression driving intrinsic or early resistance to targeted therapies in glioblastoma, EGFR mutation positive NSCLC, and melanoma.24, 25, 26